Good morning. It’s Elizabeth Cooney again, filling in for the vacationing Ed Silverman. Some food for thought to start the day. Comments, suggestions, tips welcome.
A controversial Food and Drug Administration working group has begun discussing how to import drugs from other countries as a way to bring down prices for American patients, STAT says. “That work group has met and is outlining its plan of action,” Dan Best, Trump administration senior adviser on drug pricing, said on a phone call with reporters. “As more of that information becomes available, we’ll make it available to the market.”
Strong initial demand for Amgen (AMGN) and Novartis’ (NVS) new preventive migraine therapy Aimovig has reinforced expectations of blockbuster sales — for one analyst at least, BioPharma Dive informs us. Early prescription data for Aimovig look encouraging to Leerink’s Geoffrey Porges, who calls the volume of new patient starts “very impressive” in a note to investors. Porges believes Amgen and Novartis are still working through pent-up demand for a new migraine option and estimates that as many as 75,000 patients will be taking Aimovig by the end of this year.